Your AI-Trained Oncology Knowledge Connection!

Elias Jabbour, MD, MD Anderson Cancer Center

home / authors / elias-jabbour-md-md-anderson-cancer-center

Elias Jabbour, MD, is a professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Articles

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD

Ongoing Research Efforts and More in Ph+ Acute Lymphoblastic Leukemia

Ibrahim Aldoss, MD;Elias Jabbour, MD, MD Anderson Cancer Center

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss ongoing research efforts in the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.

Safety Data With Ponatinib in PHALLCON for Ph+ Acute Lymphoblastic Leukemia

Ibrahim Aldoss, MD;Elias Jabbour, MD, MD Anderson Cancer Center

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss safety findings from the PHALLCON trial of ponatinib in Philadelphia chromosome–positive acute lymphoblastic leukemia.

Clinical Efficacy With Ponatinib in the PHALLCON Trial for Ph+ ALL

Ibrahim Aldoss, MD;Elias Jabbour, MD, MD Anderson Cancer Center

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the efficacy with ponatinib observed in the PHALLCON trial of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

The Impact of the Ponatinib FDA Approval in Newly Diagnosed Ph+ ALL

Ibrahim Aldoss, MD;Elias Jabbour, MD, MD Anderson Cancer Center

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Current Standards of Care for Ph+ Acute Lymphoblastic Leukemia

Ibrahim Aldoss, MD;Elias Jabbour, MD, MD Anderson Cancer Center

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss current standards of care for the treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Prevalence and Prognosis of Ph+ Acute Lymphoblastic Leukemia

Ibrahim Aldoss, MD;Elias Jabbour, MD, MD Anderson Cancer Center

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the prevalence and prognostic outcomes of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL

Elias Jabbour, MD, MD Anderson Cancer Center

May 19th 2023

Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.

On the Horizon: Exciting Prospects in the Acute Lymphoblastic Leukemia Treatment Landscape

Ryan D. Cassaday, MD, University of Washington/Fred Hutch;Elias Jabbour, MD, MD Anderson Cancer Center;Gary J. Schiller, MD;Armin Ghobadi, MD

March 20th 2023

Closing thoughts from a panel of ALL experts on improving access to therapy and how their field may evolve in years to come.

Emerging Data Supporting the use of Tisagenlecleucel in Patients with R/R Acute Lymphoblastic Leukemia

Ryan D. Cassaday, MD, University of Washington/Fred Hutch;Elias Jabbour, MD, MD Anderson Cancer Center;Gary J. Schiller, MD;Armin Ghobadi, MD

March 20th 2023

Led by Dr Armin Ghobadi, the panel reviews data from a study regarding CD19 CAR T-cell therapy use in adults with B-Cell ALL.

Applications for Blinatumomab in Treating Patients with R/R Acute Lymphoblastic Leukemia

Ryan D. Cassaday, MD, University of Washington/Fred Hutch;Elias Jabbour, MD, MD Anderson Cancer Center;Gary J. Schiller, MD;Armin Ghobadi, MD

March 13th 2023

Dr Cassaday discusses data supporting the use of combination blinatumomab and pembrolizumab in patients with R/R ALL.

Inotuzumab as an Option for Patients with R/R Acute Lymphoblastic Leukemia

Ryan D. Cassaday, MD, University of Washington/Fred Hutch;Elias Jabbour, MD, MD Anderson Cancer Center;Gary J. Schiller, MD;Armin Ghobadi, MD

March 13th 2023

Dr Jabbour and fellow panelists share their thoughts on the benefits of Inotuzumab ozogamicin, particularly in a pre-allogeneic HSCT setting.

CAR T-cell Therapy in Patients with R/R Acute Lymphoblastic Leukemia

Ryan D. Cassaday, MD, University of Washington/Fred Hutch;Elias Jabbour, MD, MD Anderson Cancer Center;Gary J. Schiller, MD;Armin Ghobadi, MD

March 6th 2023

Dr Schiller summarizes results from the ZUMA-3 trial and poses thoughtful questions to fellow panelists regarding clinical significance.

$Considerations for the Treatment of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia$

Considerations for the Treatment of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Ryan D. Cassaday, MD, University of Washington/Fred Hutch;Elias Jabbour, MD, MD Anderson Cancer Center;Gary J. Schiller, MD;Armin Ghobadi, MD

March 6th 2023

Best practices and special considerations for effective therapy selection and sequencing in the relapsed/refractory ALL setting.

Recently Presented Data Informing the Treatment of Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia

Ryan D. Cassaday, MD, University of Washington/Fred Hutch;Elias Jabbour, MD, MD Anderson Cancer Center;Gary J. Schiller, MD;Armin Ghobadi, MD

February 27th 2023

The panelists review highly anticipated results from the E1910 trial assessing combination blinatumomab/consolidation chemotherapy in patients with Philadelphia chromosome-negative ALL.

The Evolving Treatment Paradigm for Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Ryan D. Cassaday, MD, University of Washington/Fred Hutch;Elias Jabbour, MD, MD Anderson Cancer Center;Gary J. Schiller, MD;Armin Ghobadi, MD

February 27th 2023

Gary J. Schiller, MD and fellow panelists discuss clinical trial outcomes presented at the ASH 2022 annual meeting relevant to patients with Philadelphia chromosome-positive ALL.

Treatment Options for Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia in the Frontline Setting

Ryan D. Cassaday, MD, University of Washington/Fred Hutch;Elias Jabbour, MD, MD Anderson Cancer Center;Gary J. Schiller, MD;Armin Ghobadi, MD

February 20th 2023

Focusing on Philadelphia chromosome-positive ALL, panelists review standard-of-care treatment practices.

Assessing Minimal Residual Disease in Patients with Acute Lymphoblastic Leukemia

Ryan D. Cassaday, MD, University of Washington/Fred Hutch;Elias Jabbour, MD, MD Anderson Cancer Center;Gary J. Schiller, MD;Armin Ghobadi, MD

February 20th 2023

Four clinicians share best practices for assessing minimal residual disease (MRD) for ALL, touching on how these practices are evolving over time.

Standard Prognoses for Pediatric and Adult Patients with Acute Lymphoblastic Leukemia

Ryan D. Cassaday, MD, University of Washington/Fred Hutch;Elias Jabbour, MD, MD Anderson Cancer Center;Gary J. Schiller, MD;Armin Ghobadi, MD

February 10th 2023

Ryan Cassaday, MD, notes differences between prognoses for patients with ALL based-on age, subtype, and disease progression status.

Emergent Data Concerning Risk Factors for Acute Lymphoblastic Leukemia

Ryan D. Cassaday, MD, University of Washington/Fred Hutch;Elias Jabbour, MD, MD Anderson Cancer Center;Gary J. Schiller, MD;Armin Ghobadi, MD

February 10th 2023

Armin Ghobadi, MD, and fellow panelists discuss new data concerning patients most at risk for developing ALL.

Patient Presentation and Diagnosis in Acute Lymphoblastic Leukemia

Ryan D. Cassaday, MD, University of Washington/Fred Hutch;Elias Jabbour, MD, MD Anderson Cancer Center;Gary J. Schiller, MD;Armin Ghobadi, MD

February 3rd 2023

A panel of experts briefly reviews how both pediatric and adult patients with acute lymphoblastic leukemia (ALL) typically present and describes a standard patient workup.

Differentiating Subtypes of Acute Lymphoblastic Leukemia

Ryan D. Cassaday, MD, University of Washington/Fred Hutch;Elias Jabbour, MD, MD Anderson Cancer Center;Gary J. Schiller, MD;Armin Ghobadi, MD

February 3rd 2023

Elias Jabbour, MD, leads a discussion on the similarities and differences between ALL subtypes and their respective incidence rates.

MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALL

Jorge Cortes, MD, Georgia Cancer Center;Robin Foa, MD, Sapienza University;Elias Jabbour, MD, MD Anderson Cancer Center;Doug Smith, MD, John Hopkins Medicine

July 8th 2021

Doug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).

GIMEMA LALl2317: Sequential Chemotherapy and Blinatumomab for Adult ALL

Jorge Cortes, MD, Georgia Cancer Center;Robin Foa, MD, Sapienza University;Elias Jabbour, MD, MD Anderson Cancer Center;Doug Smith, MD, John Hopkins Medicine

July 8th 2021

Robin Foà, MD, discusses results from the GIMEMA LAL2317 sequential chemotherapy-blinatumomab frontline trial, where experts evaluated the efficacy of blinatumomab in increasing the early MRD (minimal residual disease) negativity rate.

GIMEMA LAL2116, D-ALBA, Updated Results and Prognostic Impact of IKZF1 in Ph+ ALL

Jorge E. Cortes, MD, MD Anderson Cancer Center;Robin Foa, MD, Sapienza University;Elias Jabbour, MD, MD Anderson Cancer Center;Doug Smith, MD, John Hopkins Medicine

July 8th 2021

Robin Foà, MD, leads a discussion on the primary takeaways from the GIMEMA LAL2116, D-ALBA trial, particularly the prognostic impact of the IKZF1-plus genotype and the Ikaros mutation.

Phase II Results: Ponatinib + Blinatumomab in Ph+ ALL

Jorge Cortes, MD, Georgia Cancer Center;Robin Foa, MD, Sapienza University;Elias Jabbour, MD, MD Anderson Cancer Center;Doug Smith, MD, John Hopkins Medicine

July 8th 2021

Elias Jabbour, MD, highlights early findings from a phase 2 study of the combination of ponatinib and blinatumomab in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).